The Supreme Cannabis Company Inc. (TSX: FIRE) (OTC
Post# of 316
- Shipment of medical cannabis to Israel represents a new international revenue opportunity for Supreme Cannabis
- Truverra-branded product will be sold through Israel’s largest and leading producer of medical cannabis and cannabis product
- The cannabis was grown at Supreme Cannabis’ premium, indoor, hybrid cultivation operation located in Ontario
The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a company dedicated to growing the world’s best cannabis and becoming a leader in the global cannabis industry, completed a landmark shipment of medical cannabis from Canada to Israel. The shipment contained Supreme Cannabis’ premium medical cannabis product, which will be sold through Israel’s largest and leading producer of medical cannabis and cannabis product (http://nnw.fm/Ob7vr).
Supreme Cannabis interim president and CEO Colin Moore reported that the transaction, which was made possible through a partnership with Breath of Life International (BOL Pharma), represents a new international revenue opportunity for Supreme Cannabis and “builds Truverra’s global medical brand in one of the most sophisticated medical cannabis markets in the world.”
“With the support of BOL Pharma, we navigated both Canada and Israel’s complex regulatory landscapes to achieve compliance with regulatory authorities in both countries, including Health Canada, the Canadian Food Inspection Agency and Israel’s Ministry of Health and Ministry of Agriculture and Rural Development,” Moore continued. “We benefitted from BOL Pharma’s skilled team, international experience and solidified position as a leading medical cannabis company in Israel. As we pursue capital-light international opportunities, we will continue to look to Jeff Adams, Truverra’s CEO, and his exceptional team to build Truverra’s medical brand globally.”
Supreme Cannabis’ partner in Israel, BOL Pharma has been researching and developing cannabis-based products for more than a decade and is the only company in Israel that handles all stages of cultivation and production, ensuring compliance with the strictest standards set by the Israeli Ministry of Health and EU-GMP conditions.
Supreme Cannabis is exporting a differentiated offering to Israel. Truverra’s premium positioned medical product is indoor grown and distributed in 10-gram containers to BOL Pharma’s network of pharmacies across Israel. BOL Pharma’s CEO, Dr. Tamir Gedo, spoke to the strength of Supreme Cannabis as a partner and the quality of its product, noting, “Supreme Cannabis is a partner that shares our high standards for quality and respect for patients and consumers. On March 30, Truverra products became available across pharmacies in Israel, and we are already receiving positive feedback from patients. We look forward to continuing to work with Supreme Cannabis and to offering Truverra’s premium medical cannabis to patients in Israel.”
Supreme Cannabis acquired Truverra last year in an agreement designed to secure an international medical brand and strong team with unique pharmaceutical expertise (http://nnw.fm/6mMUk). The Truverra acquisition provided a capital-light entry point into Europe’s CBD wellness market, where Truverra had successfully launched multiple CBD products through its ecommerce business, Truverra.com. This landmark shipment to Israel helps to establish Truverra as an international medical cannabis brand and provides diversified revenue opportunities for Supreme Cannabis.
The Supreme Cannabis Company is a global, diversified portfolio of distinct cannabis companies, products and brands. Since 2014, SPRWF has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies. Supreme Cannabis’ brands are backed by a focused suite of world-class operating assets that serve key functions in the value chain, including scaled cultivation, value-add processing, centralized manufacturing and product testing and research and development.
For more information, visit the company’s website at www.Supreme.ca
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer